Výběr jazyka

cs
  • bg

  • cs

  • da

  • de

  • el

  • en

  • es

  • et

  • fr

  • hr

  • hu

  • it

  • lt

  • lv

  • nl

  • no

  • pl

  • pt

  • ro

  • ru

  • sk

  • sl

  • sv

  • tr

  • uk

Čeština
  • Български

  • Čeština

  • Danske

  • Deutsch

  • ελληνική

  • English

  • Español

  • Eesti keel

  • Français

  • Hrvatski

  • Magyar

  • Italiano

  • Lietuvių

  • Latviešu

  • Nederlands

  • Norsk

  • Polski

  • Português

  • Română

  • Русский

  • Slovenský

  • Slovenski

  • Svenska

  • Türkçe

  • Українська

Co si myslíte o doplnění účtu?

* Za doplnění vašeho účtu neúčtujeme žádnou provizi

Gilead Sciences

GILD.US $ 67.94 USD

0.47 $ (0.7%)

Potenciál růstu

9.71%

Příjem z dividend

3.49%

1d
1t
1m
6m
Celou dobu

Přidat do košíku

1 lot = 1 akcie

Částka nákupu:

Makléřská provize:

Provize za převod:

Doporučení

Strong Buy

Hodnocení výkonu

DCF

73.28

ROE

0.01

ROA

-

P/S

3.33

P/B

4.52

Debt / Equity

1.57

O společnosti

Gilead Sciences is the largest American biopharmaceutical company engaged in research and development of healthcare products and has a batch production of innovative medicines. The Company was founded in 1987 by a 29-year-old doctor Michael L. Riordan. Gilead's technologies, as well as the drugs themselves, have established themselves as a leading choice when it comes to prevention and cure of the most fatal human diseases. The Company's main efforts have been focused on HIV cure development as well as various treatments of chronic hepatitis B and C, cancers, cardiovascular and respiratory diseases. Among the well-known products are Tamiflu, Atripla, Vistide, Emtriva. The latest successful project of Gilead was Sovaldi, which is an effective medicine for hepatitis C cure. The innovation has become an all-time record of sales. The company's research centers are located in the American cities of Boulder and San Dimas. The company has a rather small staff number, which is about 8,000 employees, with a fairly large turnover of almost $ 25 billion. Today Gilead Sciences boasts of being one of the most speedily developing start-ups in its field. Its headquarters are in California, though the company has its representative offices in other states of North America, as well as in Europe, Asia, and Australia.


Přihlaste se k odběru investičních nápadů analytiků Freedom Finance

Zprávu budeme zasílat jednou týdně, a to pouze s nejaktuálnějšími a nejdůležitějšími informacemi

Gratulujeme!

Nyní budete vždy vědět, do kterých akcií je výhodnější investovat